More than tripled risk of five-year mortality seen with use of complementary and alternative medicine alone compared with traditional therapies.

A unanimous United States Supreme Court decision has now removed a significant procedural hurdle for medical malpractice plaintiffs in 28 states. In this case, the Court was asked to determine whether ...

The TEPEZZA OBI trial evaluated the safety and efficacy of SC teprotumumab in patients with active TED and proptosis of 3mm or greater from baseline.

Three-year disease-free survival was 86.3% in the atezolizumab-mFOLFOX6 group vs 76.2% in the mFOLFOX6-alone group.

The new advice comes as federal dietary guidance has taken a much different stance. Health officials, alongside US Health Secretary Robert F. Kennedy Jr., have suggested people can include more red ...

Results from cohort 3 of ZUMA-2 demonstrated high objective response rates and deep remissions with a safety profile consistent with previous experience for this personalized immunotherapy. The Food ...

The table below is a review of notable updates that occurred in March 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. GZR4 (Gan ...

More participants felt "much more" in control of their diabetes, eating, and weight after switching to tirzepatide vs escalating dulaglutide. HealthDay News — For adults with type 2 diabetes (T2D) who ...

Adding durvalumab and tremelimumab-actl to lenvatinib and transarterial chemoembolization significantly improved progression free survival in patients with unresectable hepatocellular carcinoma.

Expanding eligibility for full LIS to include Medicare beneficiaries with incomes between 135 and 150 percent of FPL reduces cost-related medication nonadherence HealthDay News — Expanding eligibility ...

Batoclimab did not significantly improve proptosis responder rates vs placebo in patients with thyroid eye disease at week 24. Topline data were announced from two phase 3 trials evaluating batoclimab ...

The Food and Drug Administration (FDA) has approved extended dosing intervals for Eylea HD ® (aflibercept) for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME ...